Newsroom | 16241 results

SAN DIEGO--(BUSINESS WIRE)--Physicians and affiliated researchers from Ivy Fertility, a globally-recognized network of fertility centers, shared cutting-edge research at the 73rd Annual Meeting of the Pacific Coast Reproductive Society (PCRS) in Indian Wells, California last week. “Ivy Fertility is proud to provide the world’s most compassionate fertility care, and that commitment is supported by our investment in industry-leading science,” said Ivy Fertility CEO Lisa Van Dolah. “By continually...

WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the analytical validation of NavDx+Gyn, an important extension of the NavDx® blood test. NavDx+Gyn is a cell-free DNA-based fragmentomic profiling assay that enhances the detection and monitoring of human papillomavirus (HPV)-driven gynecologic cancers. Leveraging the robust foundation of the NavDx test, which has been validated in over 35 peer-reviewed publica...

DUBLIN--(BUSINESS WIRE)--The "2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA" report has been added to ResearchAndMarkets.com's offering. This report provides a compilation and analysis of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2024. In addition, publicly available 2024 sales data of biosimilar antibodies and proteins as well as of new biologic modalities such as gene and cell th...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced several new governance and key clinical leadership appointments. Felix J. Baker, Ph.D., will succeed Pierre Legault, BAA, MBA, CPA, CA, as chairman of the Bicycle Therapeutics Board of Directors as Mr. Legault and Richard Kender, MBA, will retire f...

LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a cell and gene therapy (“CGT”) contract development and manufacturing organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces the appointment of James Miskin as a Special Advisor. James will leverage expertise gained from a 25-year career in CGT to support ViroCell’s continued growth and technical development. James spent over 23 years at Oxford Biomedica (OXB), wit...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its growing portfolio of advanced cardiovascular solutions at the ACC's 74th Annual Scientific Session & Expo....

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Begins Shipping Platinum® Pro, Advancing Accessibility in Next-Gen Protein Sequencing™...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Epicrispr Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2024, and provided a business update. “2024 was a transformational year for Precision BioSciences as we solidified ourselves as a leading in vivo gene editing company, and we...